-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cardiovascular benefits of empagliflozin in patients with type 2 diabetes ( T2DM) have been reported; however, the underlying mechanisms remain unknown
diabetes blood vessels
The study was a randomized, open-label, 3-month, two-group clinical trial of 76 untreated T2DM patients with cardiovascular risk factors
metformin
We explored changes in clinical parameters associated with glucose metabolism and cardiovascular disease risk factors and analyzed gut microbiota using 16S rRNA gene sequencing and plasma metabolites using LC-MS
The researchers found that both groups had significant and similar reductions in glycated hemoglobin levels, as well as ease in glucose metabolism
CONCLUSIONS: Empagliflozin may be the treatment of choice for patients with type 2 diabetes at risk for cardiovascular disease; its cardiovascular benefits may be related to changes in gut microbiota and plasma metabolites
Empagliflozin may be the treatment of choice in patients with type 2 diabetes at risk for cardiovascular disease; its cardiovascular benefits may be related to changes in gut microbiota and plasma metabolites
Original source:
Xinru Deng.
Xinru Deng.
et al.
Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes .
JCEM.
2022.
https://academic.
oup.
com/jcem/advance-article/doi/10.
1210/clinem/dgac210 /6565990 Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes
Leave a comment here